Aktiesnakken — Juli 2010
-
Genmab costs eliminated but
significant value retained -
Genmab and GSK are fully committed
to develop Ofatumumab -
GEN bruge i hvert fald ikke cash på musikalske stjerner på deres CC
-
så kører vi
-
Jan Van der Winkel
-
my man
-
our man!
-
We are delighted to inform your about the amendment
-
in very short order we have found a win win way
-
major keystone
-
blockbuster flagship er Arzerra
-
we are now capable to leverage GSK financial power
-
market concerns
-
Markedet har været nervøs for fabrikssalg, emission og ofab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind